Tag: AstraZeneca
AstraZeneca, Daiichi Sankyo get Enhertu FDA approval for HER2-low metastatic breast cancer
Enhertu FDA approval : AstraZeneca and Daiichi Sankyo have secured approval for Enhertu (trastuzumab deruxtecan) from the US Food and Drug Administration for the treatment ... Read More
AstraZeneca to acquire US biotech firm TeneoTwo for up to $1.27bn
UK-based pharma giant AstraZeneca has signed a deal worth up to $1.27 billion to acquire American biotech company TeneoTwo in a move to bolster its ... Read More
AstraZeneca strikes licensing deal with RQ Bio for SARS-CoV-2 targeting mAbs
AstraZeneca has signed a licensing deal with RQ Biotechnology (RQ Bio) to gain access to a portfolio of early-stage monoclonal antibodies (mAbs) targeted against Covid-19 ... Read More
FDA refuses to approve AstraZeneca’s sBLA for Fasenra in CRSwNP
The US Food and Drug Administration (FDA) has refused to approve the supplemental biologics license application (sBLA) of AstraZeneca’s asthma drug Fasenra (benralizumab) for the ... Read More
AstraZeneca gets UK MHRA approval for Evusheld for Covid-19 prevention
AstraZeneca said that its antibody combination Evusheld (tixagevimab co-packaged with cilgavimab) has been authorized by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for ... Read More
AstraZeneca and Imperial spin-off VaxEquity enter into saRNA partnership
AstraZeneca has signed a collaboration deal with VaxEquity, a spin-off of Imperial College London, for discovering, developing, and commercializing the latter’s self-amplifying RNA (saRNA) therapeutics ... Read More
AstraZeneca to establish $360m API manufacturing facility in Ireland
AstraZeneca said that it will invest $360 million in Ireland for setting up an active pharmaceutical ingredient (API) manufacturing facility for small molecules near Dublin. ... Read More
AstraZeneca reports positive results for phase 2 COAST trial of oleclumab and monalizumab
AstraZeneca has reported positive results from the COAST phase 2 trial of its oleclumab or monalizumab in combination with Imfinzi (durvalumab) in patients with non-small ... Read More
DESTINY-Gastric02 phase 2 trial results : Enhertu shows clinically meaningful and durable tumor response
AstraZeneca said that Enhertu (trastuzumab deruxtecan) has shown clinically meaningful and durable response in the DESTINY-Gastric02 phase 2 trial featuring patients having HER2-positive advanced gastric ... Read More
AstraZeneca India scraps Dapagliflozin distribution deal with Abbott
AstraZeneca Pharma India (AstraZeneca India) said that it has scrapped its distribution agreement with Abbott Healthcare pertaining to its Type 2 diabetes drug Dapagliflozin in ... Read More
